Michael Kalos, Ph.D.

Michael Kalos, Ph.D., is a member of Lilly’s Research Oncology Division, where he leads preclinical and translational efforts in Cancer Immunotherapy. Dr. Kalos is a recognized international key thought leader in the fields of immunotherapy and biomarkers, with over 20 years experience spanning biotech, academia, and big pharma. He has authored multiple high-impact primary and review articles as well as book chapters in the field of cancer immunotherapy, has been an invited speaker at national and international scientific meetings, is a member of institutional and corporate scientific advisory boards, and steering committees for international immunotherapy societies and working groups.